<code id='61905F2018'></code><style id='61905F2018'></style>
    • <acronym id='61905F2018'></acronym>
      <center id='61905F2018'><center id='61905F2018'><tfoot id='61905F2018'></tfoot></center><abbr id='61905F2018'><dir id='61905F2018'><tfoot id='61905F2018'></tfoot><noframes id='61905F2018'>

    • <optgroup id='61905F2018'><strike id='61905F2018'><sup id='61905F2018'></sup></strike><code id='61905F2018'></code></optgroup>
        1. <b id='61905F2018'><label id='61905F2018'><select id='61905F2018'><dt id='61905F2018'><span id='61905F2018'></span></dt></select></label></b><u id='61905F2018'></u>
          <i id='61905F2018'><strike id='61905F2018'><tt id='61905F2018'><pre id='61905F2018'></pre></tt></strike></i>

          leisure time

          leisure time

          author:explore    Page View:35345
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more
          ALS treatment from Biogen, Ionis fails in study
          ALS treatment from Biogen, Ionis fails in study

          RubyWallauforSTATAplantousenewgenetictechniquestotreatnon-geneticformsofALSfailedinanearlystudy,Ioni

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          Ripples from Flovent's discontinuation is killing children with asthma

          GettyImagesAspediatricianswhotakecareofchildrenintheinpatient,emergency,andprimarycaresettings,weare